URGN
UroGen Pharma Ltd.
+0.78 (+1.79%)44.27USD295K成交股數–市值–本益比(近四季)–股價營收比+199.2%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。外國發行人(20-F)通常只申報半年或年度,逐季會有缺。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 72.5M+258% | 51.0M+107% | 27.5M+9% | 24.2M+11% | 20.3M+8% | 24.6M+4% | 25.2M+21% | 21.8M+3% | 18.8M | 23.5M | 20.9M | 21.1M |
| 營業成本 | 6.6M | 4.1M | 3.3M | 3.6M | 2.3M | – | 2.5M | 2.2M | 1.7M | – | 2.4M | 2.4M |
| 毛利 | 65.9M+268% | 46.8M+112% | 24.2M+6% | 20.7M+5% | 17.9M+5% | 22.1M+4% | 22.8M+23% | 19.6M+5% | 17.1M | 21.2M | 18.5M | 18.7M |
| 毛利率 | 90.9% | 91.9% | 88.1% | 85.3% | 88.5% | 89.9% | 90.3% | 89.8% | 90.8% | 90.3% | 88.6% | 88.4% |
| 研發費用 | 17.3M | 15.6M | 14.0M | 18.9M | 19.9M | – | 11.4M | 15.4M | 15.5M | – | 10.2M | 11.6M |
| 銷售管理費用 | 48.4M | 51.5M | 37.6M | 43.2M | 35.0M | – | 28.9M | 30.1M | 27.3M | – | 21.8M | 22.5M |
| 營業利益 | 111K-100% | −20.3M | −27.4M+56% | −41.4M+60% | −36.9M+43% | – | −17.5M+30% | −25.8M+68% | −25.7M | – | −13.5M | −15.4M |
| 營業利益率 | 0.2% | -39.8% | -99.7% | -171.2% | -182.3% | – | -69.6% | -118.3% | -137.1% | – | -64.7% | -72.8% |
| 稅後淨利 | −14.4M-67% | −23.6M-37% | −33.3M+41% | −49.9M+50% | −43.8M+36% | −37.5M+44% | −23.7M+8% | −33.4M+38% | −32.3M | −26.0M | −21.9M | −24.1M |
| 淨利率 | -19.8% | -46.3% | -121.3% | -206.2% | -216.5% | -152.7% | -93.9% | -152.9% | -171.9% | -110.6% | -104.9% | -114.2% |
| 稀釋 EPS | – | – | – | – | – | – | – | – | – | – | – | – |
| 稀釋股數 | – | – | – | – | – | – | – | – | – | – | – | – |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 79.1M | 110M | 90.0M | 92.9M | 104M | 172M | 125M | 220M | 131M | 95.0M | 119M | 20.1M |
| 應收帳款 | 88.8M | 55.4M | 19.7M | 19.6M | 19.6M | 20.3M | 22.8M | 17.4M | 14.2M | 15.4M | 12.8M | 15.5M |
| 存貨 | 24.6M | 20.9M | 8.3M | 7.1M | 7.6M | 9.2M | 7.6M | 7.4M | 7.2M | 5.7M | 5.0M | 5.0M |
| 總資產 | 253M | 254M | 185M | 209M | 248M | 286M | 302M | 282M | 201M | 178M | 194M | 95.4M |
| 有息負債 | 189M | 190M | 122M | 123M | 122M | 122M | 122M | 97.8M | 97.6M | 98.6M | 98.5M | 98.3M |
| 總負債 | 385M | 378M | 300M | 302M | 294M | 295M | 276M | 252M | 241M | 244M | 236M | 234M |
| 股東權益 | −132M | −124M | −115M | −93.4M | −46.5M | −8.8M | 25.5M | 30.3M | −40.1M | −65.2M | −42.0M | −138M |
| 負債比 | 152.4% | 149.0% | 162.4% | 144.7% | 118.8% | 103.1% | 91.5% | 89.2% | 120.0% | 136.6% | 121.7% | 245.2% |
| 淨現金(現金 − 有息負債) | −110M | −79.6M | −32.1M | −29.6M | −18.1M | 50.3M | 3.2M | 122M | 33.8M | −3.5M | 20.8M | −78.2M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −45.3M | – | – | −42.0M+32% | – | – | – | −31.7M | – | – | – |
| 資本支出 | – | 54K | – | – | 44K | – | – | – | 0.00 | – | – | – |
| 自由現金流 | – | −45.4M | – | – | −42.1M+33% | – | – | – | −31.7M | – | – | – |
| 折舊攤銷 | 100K | 75K | 100K | 100K | 72K | – | 100K | 100K | 123K | – | 200K | 200K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -89.0% | – | – | -207.7% | – | – | – | -169.0% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 110M
| Jelmyto | 94.0M | 85.6% | +4.0% |
|---|---|---|---|
| Zusduri | 15.8M | 14.4% | – |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 110M | +21.4% | −153M | -139.8% | – | −163M |
| FY2024 | 90.4M | +9.3% | −127M | -140.4% | – | −97.1M |
| FY2023 | 82.7M | +28.5% | −102M | -123.6% | – | −76.6M |
| FY2022 | 64.4M | +34.0% | −110M | -170.6% | – | −87.8M |
| FY2021 | 48.0M | +307.2% | −111M | -230.7% | -4.96 | −85.6M |
| FY2020 | 11.8M | +65450.0% | −128M | -1,088.9% | -5.90 | −107M |
| FY2019 | 18K | -98.4% | −105M | -584,144.4% | -5.12 | −71.3M |
| FY2018 | 1.1M | – | −75.7M | -6,707.2% | -4.80 | −37.9M |